Induction of lymphokine-activated killer activities in peripheral blood lymphocytes and regional lymph node lymphocytes against PC-9 cultured adenocarcinoma and autologous pulmonary adenocarcinoma cells
- PMID: 3497285
Induction of lymphokine-activated killer activities in peripheral blood lymphocytes and regional lymph node lymphocytes against PC-9 cultured adenocarcinoma and autologous pulmonary adenocarcinoma cells
Abstract
The cytotoxic activities, of the peripheral blood lymphocytes (PBL) and regional lymph node lymphocytes (LNL) generated by incubation with recombinant IL-2 (rIL-2) in vitro, have been studied to assess their effects on autologous pulmonary adenocarcinoma cells from 21 patients with lung cancer. The lymphokine-activated killer (LAK) activities of PBL were 22.9 +/- 14.8% for autologous pulmonary adenocarcinoma cells and 44.9 +/- 20% for PC-9 cells. A previous coculture of autologous tumor cells with PBL (ATS-LAK) showed no increase in induction of cytotoxicity to autologous tumor cells. The LAK activities of LNL were significantly lower than those of PBL. The cytotoxicities of rIL-2 activated lymphocytes seemed lower in well differentiated pulmonary adenocarcinoma than in moderately and poorly differentiated adenocarcinoma, and higher in patients with lymph node metastasis than in those without; they appeared, however, not to be related to clinical stage or degree of infiltration of T-zone histiocytes into the cancer stroma. The cytotoxicity to autologous tumor cells was not significantly different in the presence of the Ia antigen expressed on tumor cells, but the cytotoxicity to Ia positive PC-9 cells was significantly higher for rIL-2 activated lymphocytes from patients with lung cancer cells which were Ia positive than from those where they were Ia negative. The presence of Ia antigen on tumor cells seemed important for antitumor activity.
Similar articles
-
Tumor-draining lymph nodes of primary lung cancer patients: a potent source of tumor-specific killer cells and dendritic cells.Anticancer Res. 2005 Jan-Feb;25(1A):85-94. Anticancer Res. 2005. PMID: 15816523
-
Cytotoxicity against autologous, allogeneic, and xenogeneic tumor targets by human recombinant interleukin-2-activated lymphocytes from healthy dogs and dogs with lung tumors.Am J Vet Res. 1991 Jul;52(7):1132-6. Am J Vet Res. 1991. PMID: 1892269
-
Cytotoxicity tests against cultured human lung cancer cells with autologous lymphocytes activated in vitro by mitomycin C-treated tumor monolayers in the presence of T-cell growth factor.Jpn J Clin Oncol. 1983 Mar;13(1):3-13. Jpn J Clin Oncol. 1983. PMID: 6300483
-
Experimental evidence of interleukin-2 activity in bone marrow transplantation.Cancer J Sci Am. 1997 Dec;3 Suppl 1:S37-42. Cancer J Sci Am. 1997. PMID: 9457392 Review.
-
[Lymphocytes of the blood, regional lymph nodes and tumor tissue in breast cancer].Vopr Onkol. 1988;34(9):1040-8. Vopr Onkol. 1988. PMID: 3055674 Review. Russian. No abstract available.
Cited by
-
Natural killer and lymphokine-activated killer cell functions in chronic myeloid leukemia.Cancer Immunol Immunother. 1990;31(1):44-8. doi: 10.1007/BF01742494. Cancer Immunol Immunother. 1990. PMID: 2306755 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical